Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America

Allergologia et Immunopathologia

Volumn 42, Issue 3, 2014, Pages 245-260

  Condino Neto, A ^a   Costa Carvalho, B T ^b   Grumach, A S ^c   King, A ^d   Bezrodnik, L ^e   Oleastro, M ^f   Leiva, L ^g   Porras, O ^h   Espinosa Rosales, F J ⁱ   Franco, J L ^j   Sorensen, R U ^g,k  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c FACULDADE DE MEDICINA DO ABC   (Brazil)

^d HOSPITAL LUIS CALVO MACKENNA   (Chile)

^e HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^f HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^g LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HOSPITAL NACIONAL DE NIÑOS   (Costa Rica)

ⁱ INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^j UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^k UNIVERSIDAD DE LA FRONTERA   (Chile)

more..

Author keywords

Guidelines; Immunoglobulin replacement therapy; Intravenous immunoglobulin; Latin America; Primary immunodeficiency; Subcutaneous immunoglobulin

Indexed keywords

DIPHENHYDRAMINE; HUMAN IMMUNOGLOBULIN; HYDROCORTISONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; IMMUNOGLOBULIN;

AGAMMAGLOBULINEMIA; ARTICLE; ATAXIA TELANGIECTASIA; B LYMPHOCYTE; CELL COUNT; CLINICAL EVALUATION; COMBINED IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; DISEASE TRANSMISSION; HUMAN; HYPER IGE SYNDROME; HYPER IGM SYNDROME; IMMUNE DEFICIENCY; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOTHERAPY; INFECTION; PATIENT ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; SIDE EFFECT; SOUTH AND CENTRAL AMERICA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; PASSIVE IMMUNIZATION; PROCEDURES;

GUIDELINES AS TOPIC; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LATIN AMERICA;

EID: 84901596592     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2012.09.006     Document Type: Article

References (109)

1. Moore B.B., Moore T.A., Toews G.B. Role of T- and B-lymphocytes in pulmonary host defences. Eur Respir J 2001, 18:846-856.
2. Bierry G., Boileau J., Barnig C., Gasser B., Korganow A.S., Buy X., et al. Thoracic manifestations of primary humoral immunodeficiency: a comprehensive review. Radiographics 2009, 29:1909-1920.
3. Herriot R., Sewell W.A. Antibody deficiency. J Clin Pathol 2008, 61:994-1000.
4. Bruton O.C. Agammaglobulinemia. Pediatrics 1952, 9:722-727.
5. Al-Herz W., Bousfiha A., Casanova J.L., Chapel H., Conley M.E., Cunningham-Rundles C., et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol 2011, 2:54.
6. Leiva L.E., Zelazco M., Oleastro M., Carneiro-Sampaio M., Condino-Neto A., Costa-Carvalho B.T., et al. Primary immunodeficiency diseases in Latin America: the second report of the LAGID registry. J Clin Immunol 2007, 27:101-108.
7. Notarangelo L., Casanova J.L., Fischer A., Puck J., Rosen F., Seger R., et al. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol 2004, 114:677-687.
8. Núñez R.M. Primary immunodeficiency in Colombian children. Allergol Immunopathol (Madr) 1988, 16:273-275.
9. Bernatowska E., Madalinski K., Michalkiewicz J., Gregorek H. Primary immunodeficiency diseases in children treated in the Children's Memorial Hospital, Poland. Immunol Invest 1988, 17:107-120.
10. Hoffmann F., Grimbacher B., Thiel J., Peter H.H., Belohradsky B.H. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res 2010, 15:238-245. Vivaglobin Study Group.
11. Berger M., Murphy E., Riley P., Bergman G.E. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J 2010, 103:856-863. VIRTUE Trial Investigators.
12. Hagan J.B., Fasano M.B., Spector S., Wasserman R.L., Melamed I., Rojavin M.A., et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010, 30:734-745.
13. Hartung H.P., Mouthon L., Ahmed R., Jordan S., Laupland K.B., Jolles S. Clinical applications of intravenous immunoglobulins (IVIg)-beyond immunodeficiencies and neurology. Clin Exp Immunol 2009, 158(Suppl. 1):23-33.
14. Modell V., Gee B., Lewis D.B., Orange J.S., Roifman C.M., Routes J.M., et al. Global study of primary immunodeficiency diseases (PI)-diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res 2011, 51:61-70.
15. Notarangelo L., Casanova J.L., Conley M.E., Chapel H., Fischer A., Puck J., et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol 2006, 117:883-896.
16. Yong P.L., Boyle J., Ballow M., Boyle M., Berger M., Bleesing J., et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol 2010, 135:255-263.
17. Fried A.J., Bonilla F.A. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev 2009, 22:396-414.
18. Carvalho B.T.C., Condino-Neto A., Sole D., Filho N.R. I Consenso Brasileiro sobre o Uso de Imunoglobulina Humana em Pacientes com Imunodeficiências Primárias. Rev Bras Alerg Immunopatol 2010, 10:104-116.
19. EU PID Consensus Statement Executive Summary Consensus Conference on Primary Immunodeficiencies 2006.
20. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006, 117(Suppl. 4):S525-S535.
21. Shehata N., Palda V., Bowen T., Haddad E., Issekutz T.B., Mazer B., et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev 2010, 24(Suppl. 1):S28-S50.
22. Stiehm E.R., Orange J.S., Ballow M., Lehman H. Therapeutic use of immunoglobulins. Adv Pediatr 2010, 57:185-218.
23. Lederman H.M., Winkelstein J.A. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985, 64:145-156.
24. Quartier P., Debre M., De Blic J., de Sauverzac R., Sayegh N., Jabado N., et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999, 134:589-596.
25. Liese J.G., Wintergerst U., Tympner K.D., Belohradsky B.H. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 1992, 146:335-339.
26. Cunningham-Rundles C., Siegal F.P., Smithwick E.M., Lion-Boule A., Cunningham-Rundles S., O'Malley J. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 1984, 101:435-439.
27. Oksenhendler E., Gérard L., Fieschi C., Malphettes M., Mouillot G., Jaussaud R., et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008, 46:1547-1554.
28. Busse P.J., Razvi S., Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002, 109:1001-1004.
29. de Gracia J., Vendrell M., Alvarez A., Pallisa E., Rodrigo M.J., de la Rosa D., et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004, 4:745-753.
30. García J.M., Español T., Gurbindo M.D., Casas C.C. Update on the treatment of primary immunodeficiencies. Allergol Immunopathol (Madr) 2007, 35:184-192.
31. Winkelstein J.A., Marino M.C., Ochs H., Fuleihan R., Scholl P.R., Geha R., et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003, 82:373-384.
32. Bonilla F.A., Bernstein I.L., Khan D.A., Ballas Z.K., Chinen J., Frank M.M., et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005, 94(Suppl.):S1-S63.
33. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008, 28:413-437.
34. Bjorkander J., Hammarstrom L., Smith C.I., Buckley R.H., Cunningham-Rundles C., Hanson L.A. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 1987, 7:8-15.
35. Rachid R., Bonilla F.A. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012, 129:628-634.
36. Garcia-Lloret M., McGhee S., Chatila T.A. Immunoglobulin replacement therapy in children. Immunol Allergy Clin North Am 2008, 28:833-849.
37. Dorsey M.J., Orange J.S. Impaired specific antibody response and increased B-cell population in transient hypogammaglobulinemia of infancy. Ann Allergy Asthma Immunol 2006, 97:590-595.
38. Buckley R.H. B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review. J Allergy Clin Immunol 2010, 125:790-797.
39. Neven B., Cavazanna-Calvo M., Fischer A. Late immunologic and clinical outcomes for children with SCID. Biol Blood Marrow Transplant 2008, 14(Suppl. 1):76-78.
40. Leung D.Y., Ambrosino D.M., Arbeit R.D., Newton J.L., Geha R.S. Impaired antibody responses in the hyperimmunoglobulinemia E syndrome. J Allergy Clin Immunol 1988, 81:1082-1097.
41. Su H.C., Jing H., Zhang Q. DOCK8 deficiency. Ann NY Acad Sci 2011, 1246:26-33.
42. Wakim M., Alazard M., Yajima A., Speights D., Saxon A., Stiehm E.R. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 1998, 81:153-158.
43. Sowerwine K.J., Holland S.M., Freeman A.F. Hyper-IgE syndrome update. Ann NY Acad Sci 2012, 1250:25-32.
44. Conley M.E., Saragoussi D., Notarangelo L., Etzioni A., Casanova J.L. An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome. Clin Immunol 2003, 109:272-277.
45. Litzman J., Jones A., Hann I., Chapel H., Strobel S., Morgan G. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome. Arch Dis Child 1996, 75:436-439.
46. Nowak-Wegrzyn A., Crawford T.O., Winkelstein J.A., Carson K.A., Lederman H.M. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr 2004, 144:505-511.
47. Guerra-Maranhão M.C., Costa-Carvalho B.T., Nudelman V., Barros-Nunes P., Carneiro-Sampaio M.M., Arslanian C., et al. Response to polysaccharide antigens in patients with ataxia-telangiectasia. J Pediatr (Rio J) 2006, 82:132-136.
48. Kawai T., Malech H.L. WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol 2009, 16:20-26.
49. Rao K., Amrolia P.J., Jones A., Cale C.M., Naik P., King D., et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005, 105:879-885.
50. IUIS Scientific Committee Primary immunodeficiency diseases. Clin Exp Immunol 1999, 118(Suppl. 1):1-28.
51. Berger M. Goals of therapy in antibody deficiency syndromes. J Allergy Clin Immunol 1999, 104:911-913.
52. Grimbacher B., Schäffer A.A., Peter H.H. The genetics of hypogammaglobulinemia. Curr Allergy Asthma Rep 2004, 4:349-358.
53. Orange J.S., Grossman W.J., Navickis R.J., Wilkes M.M. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010, 137:21-30.
54. Nelson R.P., Ballow M. Immunomodulation and immunotherapy: drugs, cytokines, cytokine receptors, and antibodies. J Allergy Clin Immunol 2003, 111(Suppl):S720-S743.
55. Roifman C.M., Levison H., Gelfand E.W. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987, 1:1075-1077.
56. Bonagura V.R., Marchlewski R., Cox A., Rosenthal D.W. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008, 122:210-212.
57. Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010, 116:7-15.
58. Roifman C.M., Schroeder H., Berger M., Sorensen R., Ballow M., Buckley R.H., et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003, 3:1325-1333.
59. Landwehr L.P., Jeppson J.D., Katlan M.G., Esterl B., McCormick D., Hamilos D.L., et al. Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma. Chest 1998, 114:1349-1356.
60. Gelfand E.W., Reid B., Roifman C.M. Intravenous immune serum globulin replacement in hypogammaglobulinemia. A comparison of high- versus low-dose therapy. Monogr Allergy 1988, 23:177-186.
61. Eijkhout H.W., van Der Meer J.W., Kallenberg C.G., Weening R.S., van Dissel J.T., Sanders L.A., et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinaemia: a randomized, double-blinded, multicenter crossover trial. Ann Intern Med 2001, 135:165-174.
62. Plebani A., Soresina A., Rondelli R., Amato G.M., Azzari C., Cardinale F., et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 2002, 104:221-230.
63. Notarangelo L.D., Rawlings D.J., Sullivan K.E. An exemplum of XLA. Clin Immunol 2008, 126:137-139.
64. Lucas M., Lee M., Lortan J., Lopez-Granados E., Misbah S., Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010, 125:1354-1360.
65. Kokron CM, Barros MT. Imunodeficiências Primárias. In: Martins MA, Carrilho FJ, Avancini V, Alves F, Castilho EA, Cerri GG, Wen CL, org. Clínica Médica, vol. 7. 1ed. Sao Paulo, Brazil: Editora Mano≤ 2009. p. 145-64.
66. Dashti-Khavidaki S., Aghamohammadi A., Farshadi F., Movahedi M., Parvaneh N., Pouladi N., et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol 2009, 19:139-145.
67. Immune Deficiency Foundation patient survey. Immune Deficiency Foundation website. IDF Patient Survey; 2006. [accessed 12.08.12]. http://www.hhs.gov/ash/bloodsafety/presentations/Boyle0507.pdf.
68. Siegel J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy 2005, 25(11 Pt 2):78S-84S.
69. Brennan V.M., Salomé-Bent L, Chapel H.M. Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003, 133:247-251.
70. Brennan V.M., Cochrane S., Fletcher C., Hendy D., Powell P. Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home. J Clin Immunol 1995, 15:116-119.
71. Berger M., Pinciaro P.J., Flebogamma 5Investigators Safety, efficacy and pharmacokinetics of Flebogamma 5 for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 2004, 24:389-396.
72. Roifman C.M. Intravenous immunoglobulin treatment of immunodeficiency. Preface. Immunol Allergy Clin North Am 2008, 28:xv-xvi.
73. Gelfand E.W. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006, 6:592-599.
74. Pierce L.R., Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003, 17:241-254.
75. Schiavotto C., Ruggeri M., Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993, 78(6 Suppl. 2):35-40.
76. FDA Dear Manufacturer: immune globulin intravenous (human) (IGIV); required updates to product labeling 2003, [accessed 12.08.12]. http://www.fda.gov/cber/ltr/IgIV101603.htm.
77. Yin F., Nesbitt J.A., Tobian A.A., Holt P.A., Mikdashi J. Hemolytic anemia following intravenous immunoglobulin administration. Am J Hematol 2008, 83:825.
78. Immune Deficiency Foundation IDF guide for nurses 2011, Available at: http://cipo.ca/Nurses_Guide.pdf [accessed 12.08.12].
79. Jolles S., Kaveri S.V., Orange J. Intravenous immunoglobulins. Current understanding and future directions. Clin Exp Immunol 2009, 158:S68-S70.
80. The International Patient Organization for Primary Immunodeficiencies (IPOPI) is an international not for profit organization dedicated to improving awareness, access to early diagnosis and optimal treatments for primary immunodeficiency (PID) patients worldwide. http://www.ipopi.org/.
81. Horowitz B., Wiebe M.E., Lippin A., Stryker M.H. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion (Paris) 1985, 25:516-522.
82. Siegel J. Safety considerations in IGIV utilization. Int Immunopharmacol 2006, 6:523-527.
83. Wang J., Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005, 25:57-62.
84. Michel M., Chanet V., Galicier L., Ruivard M., Levy Y., Hermine O., et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 2004, 83:254-263.
85. Renal insufficiency and failure associated with immune globulin intravenous therapy United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999, 48:518-521.
86. FDA Drug Safety Warning, September 24, 1999 IVIG & Acute Renal Failure. Complete prescribing information for all current FDA approved IGIV products. [accessed 12.08.12]. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm105901.htm.
87. Sorensen R. Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin. J Manag Care Pharm 2007, 13:278-283.
88. Wiles C.M., Brown P., Chapel H., Guerrini R., Hughes R.A., Martin T.D., et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry 2002, 72:440-448.
89. Marodi L. Regulation of anti-inflammatory activity of intravenous immunoglobulin via inhibitory Fc gamma receptors. Pediatr Res 2001, 50:551.
90. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001, 345:747-755.
91. Shah S. Practical considerations for the use of IGIV therapy: introduction. Am J Health Syst Pharm 2005, 62(16 Suppl. 3):S3-S4.
92. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002, 59(12 Suppl. 6):S28-S32.
93. Condino-Neto A., Franco J.L., Trujillo-Vargas C., Espinosa-Rosales F.J., Leiva L.E., Rodriguez-Quiroz F., et al. Critical issues and needs in management of primary immunodeficiency diseases in Latin America. Allergol Immunopathol (Madr) 2011, 39:45-51.
94. Cardona A.D., Segura C.A.M. Public health policies as regards the elderly in Colombia. Rev Esp Geriatr Gerontol 2011, 46:96-99.
95. Sorensen R.U., Kallick M.D., Berger M. Home treatment of antibody deficiency syndromes with intravenous immunoglobulin. J Allergy Clin Immunol 1987, 80:810-815.
96. Ashida E.R., Saxon A. Home intravenous immunoglobulin therapy by self-administration. J Clin Immunol 1986, 6:306-309.
97. Chapel H., Brennan V. Self-infusion with immunoglobulin at home. J Clin Pathol 1991, 44:358-359.
98. Stiehm E.R., Casillas A.M., Finkelstein J.Z., Gallagher K.T., Groncy P.M., Kobayashi R.H., et al. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol 1998, 101:848-849.
99. Radinsky S., Bonagura V. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J Allergy Clin Immunol 2003, 112:630-633.
100. Gardulf A., Nicolay U., Asensio O., Bernatowska E., Böck A., Carvalho B.C., et al. Rapid subcutaneous immunoglobulin replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study. J Clin Immunol 2006, 26:177-185.
101. Gardulf A., Björvell H., Andersen V., Björkander J., Ericson D., Frøland S.S., et al. Lifelong treatment for primary antibody deficiencies: the patients' experience of subcutaneous self-infusions and home therapy. J Adv Nurs 1995, 21:917-927.
102. Gardulf A., Nicolay U., Math D., Asensio O., Bernatowska E., Böck A., et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004, 114:936-942.
103. Abrahamsen T.G., Sandersen H., Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 1996, 98:1127-1131.
104. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004, 112:1-7.
105. Hogy B., Keinecke H.-O., Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German Statutory Health Insurance. Eur J Health Econom 2005, 50:24-29.
106. Gardulf A., Andersen V., Bjorkander J., Ericson D., Frøland S.S., Gustafson R., et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995, 345:365-369.
107. Beaute J., Levy P., Millet V., Debre M., Dudoit Y., Le Mignot L., et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol 2010, 160:240-245.
108. Chapel H.M., Spickett G.P., Ericson D., Engl W., Eibl M.M., Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000, 20:94-100.
109. Nahirniak S., Hume H.A. Guidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation. Transfus Med Rev 2010, 24(Suppl. 1):S1-S6.